MedTrace Logo

Plasma Circulating Tumor DNA Analyses in ER+ Metastatic Breast Cancer

NCT03161834 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2021-05-21

No results posted yet for this study

Summary

The purpose of this study is to evaluate whether increased mutant ESR1 allele fraction in plasma ctDNA 3-6 weeks after initiating salvage endocrine therapy is predictive of progression free survival in patients with ER+ metastatic breast cancer.

Conditions

Interventions

OTHER

Observational

Sponsors & Collaborators

  • UNC Lineberger Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Gaorav P Gupta, MD, PhD · University of North Carolina, Chapel Hill

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-13
Primary Completion
2020-07-09
Completion
2020-07-09

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03161834 on ClinicalTrials.gov